Drug intelligence / Profile preview

NTZ-1091

Development stage: Preclinical
Lead developer: NTZ Lab
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

NTZ-1091 is a small molecule lead compound developed by NTZ Lab, a research company based in Sofia, Bulgaria. It functions as a selective monoamine oxidase B (MAO-B) inhibitor and is specifically designed as a radioligand prototype for imaging and diagnostic applications in central nervous system (CNS) disorders. The compound features improved physicochemical properties intended to enhance target engagement and imaging quality. NTZ-1091 is being investigated for its potential in managing and diagnosing neurodegenerative and psychiatric conditions, including Parkinson's disease, Alzheimer's disease, dementia, and depression. It is currently in the preclinical stage of development.

Targets

MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on NTZ-1091.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTZ-1091.

Explore the full profile